For the roughly half-billion people worldwide living with low back pain at any given moment, treatment options that are safe, affordable, and non-pharmacological remain frustratingly limited. Clinical guidelines have long been agnostic—or outright skeptical—about lumbar belts, citing weak evidence. A rigorous multicenter trial now challenges that stance with the strongest data yet in favor of soft, extensible supports.
Conducted across 17 French medical centers between 2021 and 2024, this open-label randomized clinical trial enrolled 168 adults experiencing nonspecific low back pain lasting between one and six months—a subacute population that is frequently undertreated and at high risk of chronification. Participants were randomized to either 12 weeks of a nonrigid lumbar belt worn alongside usual care, or usual care alone. The primary endpoint was change in the Oswestry Disability Index (ODI), a validated 0–100 functional disability scale, assessed at weeks 4 and 12. Pain intensity was also tracked weekly via online questionnaires. The primary analysis drew on 155 patients who completed at least one post-randomization assessment, with the belt group demonstrating superior ODI improvement compared with controls by week 12.
This trial matters for several reasons beyond its primary result. Subacute low back pain—pain persisting one to six months—sits at the critical window where intervention may prevent transition to chronic disability, and yet this cohort is underrepresented in most belt trials, which have focused on acute episodes or occupational prevention. The nonrigid belt design is also clinically relevant; concerns about muscle atrophy and dependency have historically applied more to rigid orthoses. Limitations include the open-label design (blinding is inherently impossible with a wearable device), the modest sample size of 168, and a predominantly female French cohort that may limit generalizability. Adherence to belt-wearing and co-interventions within usual care were likely variable across 17 sites. Nonetheless, as a prospective RCT published in JAMA Network Open, this represents a meaningful upgrade over prior observational data and warrants updated consideration in international guideline reviews.